TY - JOUR
T1 - Stable β-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice
AU - Gau, Jen Tzer
AU - Steinhilb, Michelle L.
AU - Kao, Tzu Cheg
AU - D'Amato, Constance J.
AU - Gaut, James R.
AU - Frey, Kirk A.
AU - Turner, R. Scott
N1 - Funding Information:
Supported by a Paul Beeson Physician Faculty Scholar in Aging Research Award from the American Federation for Aging Research, United States Public Health Service grant P50 AG08671 , and the Veterans Affairs Medical Center Geriatrics Research Education and Clinical Center.
PY - 2002
Y1 - 2002
N2 - We examined presynaptic cholinergic markers and β-secretase activity during progressive central nervous system amyloidogenesis in Tg2576 Alzheimer mice (transgenic for human amyloid precursor protein Swedish mutation; hAPPswe). At 14, 18, and 23 months of age there were no significant differences between wild-type and transgenic mice in four distinct central nervous system cholinergic indices - choline acetyltransferase and acetylcholinesterase activities, and binding to vesicular acetylcholine transporter and Na+-dependent high-affinity choline uptake sites. A novel enzyme-linked immunosorbent assay measuring only the secreted human β-secretase cleavage product (APPsβswe) of APPswe also revealed no change with aging in Tg2576 mouse brain. In contrast, transgenic but not wild-type mice exhibited an age-dependent increase in soluble Aβ40 and Aβ42 levels and progressive amyloid deposition in brain. Thus, aging Tg2576 mice exhibited presynaptic cholinergic integrity despite progressively increased soluble Aβ40 and Aβ42 levels and amyloid plaque density in brain. Older Tg2576 mice may best resemble preclinical or early stages of human Alzheimer's disease with preserved presynaptic cholinergic innervation. Homeostatic APPsβswe levels with aging suggest that progressive amyloid deposition in brain results not from increased β-secretase cleavage of APP but from impaired Aβ/amyloid clearance mechanisms.
AB - We examined presynaptic cholinergic markers and β-secretase activity during progressive central nervous system amyloidogenesis in Tg2576 Alzheimer mice (transgenic for human amyloid precursor protein Swedish mutation; hAPPswe). At 14, 18, and 23 months of age there were no significant differences between wild-type and transgenic mice in four distinct central nervous system cholinergic indices - choline acetyltransferase and acetylcholinesterase activities, and binding to vesicular acetylcholine transporter and Na+-dependent high-affinity choline uptake sites. A novel enzyme-linked immunosorbent assay measuring only the secreted human β-secretase cleavage product (APPsβswe) of APPswe also revealed no change with aging in Tg2576 mouse brain. In contrast, transgenic but not wild-type mice exhibited an age-dependent increase in soluble Aβ40 and Aβ42 levels and progressive amyloid deposition in brain. Thus, aging Tg2576 mice exhibited presynaptic cholinergic integrity despite progressively increased soluble Aβ40 and Aβ42 levels and amyloid plaque density in brain. Older Tg2576 mice may best resemble preclinical or early stages of human Alzheimer's disease with preserved presynaptic cholinergic innervation. Homeostatic APPsβswe levels with aging suggest that progressive amyloid deposition in brain results not from increased β-secretase cleavage of APP but from impaired Aβ/amyloid clearance mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=0036169190&partnerID=8YFLogxK
U2 - 10.1016/S0002-9440(10)64893-6
DO - 10.1016/S0002-9440(10)64893-6
M3 - Article
C2 - 11839594
AN - SCOPUS:0036169190
SN - 0002-9440
VL - 160
SP - 731
EP - 738
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 2
ER -